

IN THE CLAIMS:

Please cancel claim 1 without prejudice or disclaimer. Please amend claims 12, 13, 15 through 19, and 21 through 24 as set forth below. Applicants note that all claims currently pending in the application are shown below for clarity, except claim 1, which is canceled herein.

12. (Amended) A sustained-release, liquid formulation dosage form comprising:
a capsule comprising an expandable layer which expands upon contact with fluid; and
a self-emulsifying drug formulation.
13. (Amended) The dosage form of claim 12, wherein the expandable layer comprises an osmotic hydrogel, an osmotically effective solute, and a hydroxyalkylcellulose.
14. The dosage form of claim 13 comprising a semipermeable membrane surrounding the capsule and having an exit orifice formed or formable therein.
15. (Amended) The dosage form of claim 14, wherein the membrane comprises a cellulose acetate and a polyethylene glycol.
16. (Amended) The dosage form of claim 14, wherein the self-emulsifying drug formulation comprises a drug selected from the group consisting of a peptide, protein, protein anabolic hormone, growth promoting hormone, endocrine system hormone, porcine growth promoting hormone, bovine growth promoting hormone, equine growth promoting hormone, human growth promoting hormone, hormone derived from a pituitary gland, hormone derived from a hypothalamus gland, recombinant DNA, somatotropin, gonadotropic releasing hormone, follicle stimulating hormone, luteinizing hormone, LH-RH, insulin, colchicine, chorionic gonadotropin, oxytocin, vasopressin, desmopressin, adrenocorticotrophic hormone, prolactin, bypressin, thyroid stimulating hormone, secretin, pancreaticozym, enkephalin and glucagon.
17. (Amended) The dosage form of claim 14, wherein the self-emulsifying drug formulation comprises a surfactant selected from the group consisting of polyoxyethylenated castor oil

comprising 9 moles to 52 moles of ethylene oxide, polyoxyethylenated sorbitan monopalmitate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 4 moles of ethylene oxide, polyoxyethylenated sorbitan tristearate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan trioleate comprising 20 moles of ethylene oxide, polyoxyethylenated stearic acid comprising 8 moles of ethylene oxide, polyoxyethylene lauryl ether, polyoxyethylenated stearic acid comprising 40 moles to 50 moles of ethylene oxide, polyoxyethylenated stearic acid comprising 50 moles of ethylene oxide, polyoxyethylenated stearyl alcohol comprising 2 moles of ethylene oxide, and polyoxyethylenated oleyl alcohol comprising 2 moles of ethylene oxide.

18. (Amended) A sustained-release, liquid formulation dosage form comprising a capsule comprising an expandable layer which expands upon contact with fluid; and a self-emulsifying drug formulation comprising a drug, a surfactant, and an oil selected from the group consisting of a vegetable, mineral, animal and marine oil, an ester of an unsaturated fatty acid, a monoglyceride, a diglyceride, a triglyceride, an acetylated glyceride, olein, palmitin, stearin, lauric acid hexylester, oleic acid, oleylester, glycolyzed ethoxylated glycerides of oils, fatty acids comprising 13 molecules of ethyleneoxide, and oleic acid decylester.

19. (Amended) The dosage form of claim 18, wherein the expandable layer comprises an osmotic hydrogel, an osmotically effective solute, and a hydroxyalkylcellulose.

20. The dosage form of claim 19 comprising a semipermeable membrane surrounding the capsule and having an exit orifice formed or formable therein.

21. (Amended) The dosage form of claim 20, wherein the semipermeable membrane comprises a cellulose acetate and a polyethylene glycol.

22. (Amended) The dosage form of claim 20, wherein the drug is selected from the group consisting of a peptide, protein, protein anabolic hormone, growth promoting hormone, endocrine system hormone, porcine growth promoting hormone, bovine growth promoting hormone, equine growth promoting hormone, human growth promoting hormone, hormone derived from a pituitary gland, hormone derived from a hypothalamus gland, recombinant DNA, somatotropin, gonadotropic releasing hormone, follicle stimulating hormone, luteinizing hormone, LH-RH, insulin, colchicine, chorionic gonadotropin, oxytocin, vasopressin, desmopressin, adrenocorticotrophic hormone, prolactin, bypressin, thyroid stimulating hormone, secretin, pancreozymin, enkephalin and glucagon.

23. (Amended) The dosage form of claim 20, wherein the surfactant is selected from the group consisting of polyoxyethylenated castor oil comprising 9 moles to 52 moles of ethylene oxide, polyoxyethylenated sorbitan monopalmitate comprising 20 of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 4 moles of ethylene oxide, polyoxyethylenated sorbitan tristearate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan trioleate comprising 20 moles of ethylene oxide, polyoxyethylenated stearic acid comprising 8 moles of ethylene oxide, polyoxyethylene lauryl ether, polyoxyethylenated stearic acid comprising 40 moles to 50 moles of ethylene oxide, polyoxyethylenated stearic acid comprising 50 moles of ethylene oxide, polyoxyethylenated stearyl alcohol comprising 2 moles of ethylene oxide, and polyoxyethylenated oleyl alcohol comprising 2 moles of ethylene oxide.

24. (Amended) The dosage form of claim 20, wherein the semipermeable membrane comprises a thermoplastic polymer composition having a softening point of 40°C to 180°C.